Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 931 to 945 of 1561 results for do not do recommendations

  1. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (TA329)

    Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.

    Technology appraisal guidance
    Published
    25 February 2015
    View recommendations

    Sections for TA329

  2. What is the most clinically and cost-effective pathway for diagnosing clinically significant prostate cancer?

    Recommendation ID NG131/4 Question What is the most clinically and cost-effective pathway for diagnosing clinically significant prostate

    Research recommendation
    Published
    7 January 2022

  3. Pazopanib for the first-line treatment of advanced renal cell carcinoma (TA215)

    Evidence-based recommendations on pazopanib (Votrient) for previously untreated advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Last updated
    1 August 2013
    View recommendations

    Sections for TA215

  4. Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures (TA279)

    Evidence-based recommendations on percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures in adults.

    Technology appraisal guidance
    Published
    24 April 2013
    View recommendations

    Sections for TA279

  5. Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (TA515)

    Evidence-based recommendations on eribulin (Halaven) for treating locally advanced or metastatic (secondary) breast cancer in adults who have had only 1 course of chemotherapy.

    Technology appraisal guidance
    Published
    28 March 2018
    View recommendations

    Sections for TA515

  6. Ritlecitinib for treating severe alopecia areata in people 12 years and over (TA958)

    Evidence-based recommendations on ritlecitinib (Litfulo) for treating severe alopecia areata in people 12 years and over.

    Technology appraisal guidance
    Published
    27 March 2024
    View recommendations

    Sections for TA958

  7. Early pregnancy assessment units: A national evaluation of early pregnancy assessment unit service provision should be carried out to identify factors affecting outcomes. Factors should include whether care is provided in a dedicated unit, staffing configuration and opening hours of dedicated services. Outcomes should include both process (service) outcomes and pregnancy-related outcomes. Data collected should be used to analyse the cost effectiveness of early pregnancy assessment units compared with other models of care.

    Recommendation ID NG126/01 Question Early pregnancy assessment units: A national evaluation of early pregnancy assessment unit service

    Research recommendation
    Published
    17 December 2021

  8. The experiences of people with learning disabilities and mental health problems in services:- What experience do people with learning disabilities have of services designed to prevent and treat mental health problems and how does this relate to clinical outcomes?

    Recommendation ID NG54/6 Question The experiences of people with learning disabilities and mental health problems in services:- What...

    Research recommendation
    Published
    17 October 2016

  9. Current evidence on the safety of ultrasound-guided high‑intensity transcutaneous focused ultrasound for symptomatic uterine fibroids shows there are well-recognised complications including skin burns. The evidence on efficacy is limited in quality. Therefore, this procedure should only be used with  special arrangements   for clinical governance, consent, and audit or research.

    Recommendation ID IPG657/1 Question Current evidence on the safety of ultrasound-guided high‑intensity transcutaneous focused ultrasound

    Research recommendation
    Published
    15 November 2019

  10. What is the most clinically and cost-effective pathway for diagnosing clinically significant prostate cancer?

    Recommendation ID NG131/3 Question What is the most clinically and cost-effective pathway for diagnosing clinically significant prostate

    Research recommendation
    Published
    25 October 2019

  11. What is the natural history of people with a Likert score on MRI of less than 3 without biopsy at long-term follow‑up?

    Recommendation ID NG131/5 Question What is the natural history of people with a Likert score on MRI of less than 3 without biopsy at...

    Research recommendation
    Published
    25 October 2019

  12. Radiofrequency denervation for osteoarthritic knee pain (HTG686)

    Evidence-based recommendations on radiofrequency denervation for osteoarthritic knee pain. This involves applying heat (radiofrequency) energy to damage the nerves (denervation) that are causing pain in the knee.

    HealthTech guidance
    Published
    28 June 2023
    View recommendations

    Sections for HTG686

  13. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217)

    Evidence-based recommendations on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa) for treating Alzheimer's disease in adults.

    Technology appraisal guidance
    Last updated
    20 June 2018
    View recommendations

    Sections for TA217

  14. The evidence for treating an acute migraine attack is adequate but, for treating subsequent attacks, is limited in quality and quantity. So, for treating acute migraine, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. Find out what special arrangements mean on the NICE interventional procedures guidance page . The evidence for preventing migraine is inadequate in quality. So, for preventing migraine, this procedure should only be used in the context of research. Find out what only in research means on the NICE interventional procedures guidance page.

    Recommendation ID IPG740/01 Question The evidence for treating an acute migraine attack is adequate but, for treating subsequent attacks

    Research recommendation
    Published
    7 November 2022

  15. What are the long-term outcomes of different management strategies for primary hyperparathyroidism? Which strategies are most cost effective?

    Recommendation ID NG132/3 Question What are the long-term outcomes of different management strategies for primary hyperparathyroidism?

    Research recommendation
    Published
    25 October 2019